PTPI
PINK Petros Pharmaceuticals Inc$0.0033 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.0033, and at the day’s high of $0.0045
- YTD change
- -58.49%
- vs 20-day SMA
- -37.72%
- vs 200-day SMA
- -48.50%
Price ranges
Price & Performance
+0.00 (+13.33%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $1,489.9700
- PTPI is down 58% since the beginning of the year
- PTPI is down 87% over the past 12 months
- PTPI is down 8% over the past 1 month
- 0% of all PTPI investors are betting against PTPI
PTPI reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -72.8%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -17.50%
- vs 8-day SMA
- -27.37%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharma co-vigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, an FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
